Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients

K. Margiotti, F. Sangiuolo, A. De Luca, F. Froio, C. L. Pearce, V. Ricci-Barbini, F. Micali, M. Bonafe, C. Franceschi, B. Dallapiccola, G. Novelli, J. K V Reichardt

Research output: Contribution to journalArticlepeer-review

Abstract

We have investigated the contributions of three polymorphic markers in the SRD5A2 gene to prostate cancer in a group of Italian patients. We have genotyped cases and controls for a polymorphic (TA)n dinucleotide repeat and two functional substitutions, A49T and V89L, substituting respectively alanine with threonine at codon 49, and valine to leucine at codon 89. We found a substantially increased but not significant risk associated with the 49T mutation and a reduction of risk for the V89L substitution. In conclusion, we report on preliminary evidence for both increased and decreased risk associated with separate markers at this locus.

Original languageEnglish
Pages (from-to)147-150
Number of pages4
JournalDisease Markers
Volume16
Issue number3-4
Publication statusPublished - 2000

Keywords

  • Polymorphic variant
  • Prostate cancer
  • Prostate cancer risk
  • SRD5A2 gene

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients'. Together they form a unique fingerprint.

Cite this